284461-74-1

Basic information

• Product Name: Sorafenib related compound 12
• Synonyms: Sorafenib related compound 12;Sorafenib Impurity 12;Sorafenib Related Compound 14;Sorefinib-D4
• CAS NO: 284461-74-1
• Molecular Formula: C₂₀H₁₄ClF₃N₄O₃
• Molecular Weight: 450.7983696
• Mol File: 284461-74-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 507.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.513±0.06 g/cm3(Predicted)
• PKA: 12.90±0.70(Predicted)
• CAS DataBase Reference: Sorafenib related compound 12(CAS DataBase Reference)
• NIST Chemistry Reference: Sorafenib related compound 12(284461-74-1)
• EPA Substance Registry System: Sorafenib related compound 12(284461-74-1)

Safety Data

• Hazardous Substances Data: 284461-74-1(Hazardous Substances Data)

Usage

Uses

N-Desmethyl Sorafenib is a metabolite of Sorafenib (S676850) and has anti-proliferative activity in human breast cancer cells.

Upstream product

• 284462-80-2 4-(4-aminophenoxy)-2-pyridinecarboxamide 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 123-30-8 4-amino-phenol 
• 51727-15-2 4-chloro-2-pyridine carboxylic acid chloride hydrochloride 
• 99586-65-9 4-chloropicolinamide 
• 176977-85-8 methyl 4-chloro-2-pyridinecarboxylate hydrochloride 
• 176977-85-8 methyl 4-chloropyridine-2-carboxylate hydrochloride 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 349-65-5 2-Methoxy-5-trifluoromethyl-aniline 
• 530-62-1 1,1'-carbonyldiimidazole 
• 573673-43-5 methyl 4‐(4‐(3‐(4‐chloro‐3‐(trifluoromethyl)phenyl)ureido)phenoxy)picolinate 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 

Downstream Products

• 583840-04-4 BAY 68-7769 
• 1012059-03-8 1-(4-(2-(aminomethyl)pyridin-4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 

Relevant articles and documents

ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY

This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

DIARYL UREAS AND COMBINATIONS

The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I) : B-NH-C(O)-NH-L-M-L1-(Q)1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. Each Q is independently C(O)R4, C(O)OR4 and C(O)NR4R5; and L' is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.